The spectrum of MOG autoantibody-associated demyelinating diseases
- PMID: 23797245
- DOI: 10.1038/nrneurol.2013.118
The spectrum of MOG autoantibody-associated demyelinating diseases
Abstract
Myelin oligodendrocyte glycoprotein (MOG) has been identified as a target of demyelinating autoantibodies in animal models of inflammatory demyelinating diseases of the CNS, such as multiple sclerosis (MS). Numerous studies have aimed to establish a role for MOG antibodies in patients with MS, although the results have been controversial. Cell-based immunoassays using MOG expressed in mammalian cells have demonstrated the presence of high-titre MOG antibodies in paediatric patients with acute disseminated encephalomyelitis, MS, aquaporin-4-seronegative neuromyelitis optica, or isolated optic neuritis or transverse myelitis, but only rarely in adults with these disorders. These studies indicate that MOG antibodies could be associated with a broad spectrum of acquired human CNS demyelinating diseases. This Review article discusses the current literature on MOG antibodies, their potential clinical relevance, and their role in the pathogenesis of MOG antibody-associated demyelinating disorders.
Similar articles
-
Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.Brain. 2020 May 1;143(5):1431-1446. doi: 10.1093/brain/awaa102. Brain. 2020. PMID: 32412053
-
E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.Eur J Paediatr Neurol. 2020 Nov;29:2-13. doi: 10.1016/j.ejpn.2020.10.006. Epub 2020 Nov 4. Eur J Paediatr Neurol. 2020. PMID: 33162302 Review.
-
Clinical and MRI phenotype of children with MOG antibodies.Mult Scler. 2016 Feb;22(2):174-84. doi: 10.1177/1352458515587751. Epub 2015 Jun 3. Mult Scler. 2016. PMID: 26041801 Free PMC article.
-
MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.J Neurol. 2020 Jun;267(6):1632-1642. doi: 10.1007/s00415-020-09755-x. Epub 2020 Feb 13. J Neurol. 2020. PMID: 32055995 Free PMC article.
-
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?Front Immunol. 2018 Nov 29;9:2753. doi: 10.3389/fimmu.2018.02753. eCollection 2018. Front Immunol. 2018. PMID: 30555462 Free PMC article. Review.
Cited by
-
Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.Nat Rev Neurol. 2015 Mar;11(3):143-56. doi: 10.1038/nrneurol.2014.260. Epub 2015 Jan 27. Nat Rev Neurol. 2015. PMID: 25623793 Review.
-
MOG antibody-associated diseases.Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e60. doi: 10.1212/NXI.0000000000000060. eCollection 2015 Feb. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 25635258 Free PMC article. No abstract available.
-
Aquaporin-4 autoimmunity.Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e110. doi: 10.1212/NXI.0000000000000110. eCollection 2015 Aug. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26185772 Free PMC article. Review.
-
Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations.Nat Rev Neurol. 2020 Mar;16(3):154-170. doi: 10.1038/s41582-020-0313-y. Epub 2020 Feb 20. Nat Rev Neurol. 2020. PMID: 32080393 Review.
-
Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study.Neurol Neuroimmunol Neuroinflamm. 2020 Mar 13;7(3):e705. doi: 10.1212/NXI.0000000000000705. Print 2020 May. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32170045 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources